|
 U.S. stock index futures rose on Tuesday
as investors turned optimistic that Washington and Beijing would
agree on a deal to end a bruising trade war that is posing one
of the biggest risks to global economic growth.
|
|
 (Bloomberg) -- Kohl's Corp. fell the most in almost three years after posting quarterly sales that trailed analysts' projections. The retailer also cut its full-year profit forecast for a second time this year, exacerbating concerns about department stores.Same-store sales, a key metric for retailers, increased 0.4% in the third quarter, compared with the 0.8% growth seen by analysts, according to Consensus Metrix. Kohl's now says profit excluding some items will be $4.75 to $4.95 -- with the new high point of the range 50 cents below the previous outlook. See more results here.Key InsightsWhile Chief Executive Officer Michelle Gass said the retailer was entering the crucial holiday period with "momentum" and is "strategically increasing" investment to boost growth and traffic, the results fueled investor concern. She said on a call after the earnings release that Kohl's is increasing its focus to attract millennial shoppers. Kohl's has been trying to set itself apart from the department-store segment, which has struggled to adapt to broad changes in consumer habits, by using partnerships and smaller-store formats. The results suggest the company needs to do more, however.The chain is banking on its alliance with Amazon.com Inc., which lets customers return Amazon purchases at the more than 1,000 Kohl's locations. Gass said on the call that executives are confident the partnership "will have a positive contribution to operating income in 2019." Kohl's goal: To get customers making returns to browse ai
|
|
 Shares of Medtronic PLC surged 2.4% in premarket trading Tuesday, after the medical technology company reported fiscal second-quarter earnings that rose above expectations, and raised its full-year profit outlook, but the stock slipped 1.1% in premarket trading to extend a pullback from the previous session's all-time intraday high. Net income for the quarter to Oct. 25 rose to $1.36 billion, or $1.01 a share, from $1.12 billion, or 82 cents a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share came to $1.31, above the FactSet consensus of $1.28. Revenue rose 3.0% to $7.71 billion, above the FactSet consensus of $7.66 billion, as beats in diabetes, restorative therapies and minimally invasive therapies segment revenue offset a slight miss in cardiac and vascular revenue. For fiscal 2020, the company affirmed its revenue growth outlook of 4.0% but raised its adjusted EPS guidance range to $5.57 to $5.63 from $5.54 to $5.60. The stock had closed at a record $112.06 on Friday, then rose to an record intraday high of $114.46 on Monday before reversing to closed down 0.7%. The stock has rallied 22.3% year to date through Monday, while the S&P 500 has climbed 24.5%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
|
|
Private Label